#China #Shanghai #CAR-T therapy #lymphoma treatment #Jiahui Health

A Journey of Hope: CAR-T Therapy from Pakistan to Shanghai

In an inspiring turn of events, a 36-year-old Pakistani man named Muhammad has made significant strides in his battle against lymphoma, a form of aggressive blood cancer, through the revolutionary CAR-T therapy. After exhausting all standard treatment options locally, he traveled to Shanghai, China, to receive personalized immunotherapy at Jiahui International Cancer Center. This journey underscores both the capabilities of advanced medical technologies and the importance of patient-centric care.

Setting the Stage

Muhammad, who works in healthcare in Quetta, Pakistan, was diagnosed with diffuse large B-cell lymphoma (DLBCL). Despite undergoing several cycles of chemotherapy and an unsuccessful stem cell transplant, his condition worsened by early 2026, escalating to stage IVB with widespread metastasis to his lungs, pleura, and bones. His persistent and intense pain made life challenging.

Local physicians concluded that conventional treatments yielded no effective results, prompting them to recommend advanced therapy options available abroad. After necessary approvals from the National Medical Council of Pakistan, Muhammad set out to find the best healthcare facilities that could offer the required advanced treatments.

Choosing Jiahui Health

After exploring various medical institutions worldwide, Muhammad decided on Jiahui Health, primarily due to its efficiency in consultations and the personalized care approach it employs throughout the treatment process. He felt that the center's commitment to patient support was vital, especially given the complexities of his disease.

Upon arrival, Dr. Hao Siguo, the head of Hematology at Jiahui, evaluated Muhammad's condition. Given the extensive tumor burden, Dr. Hao crafted a personalized CAR-T treatment regimen, which involved a bridge therapy that included chemotherapy and local radiotherapy to minimize the tumor size before proceeding with the actual CAR-T cell infusion. This prior treatment played a crucial role in lowering the infusion risks and enhancing the overall treatment effectiveness.

A Successful Treatment Journey

With the patient's organ functions stable, the multidisciplinary team initiated the CAR-T therapy protocol. The treatment process began with the collection of Muhammad's lymphocytes, a critical first step in CAR-T therapy, followed by preparatory therapies to ensure his physical condition was optimal for a safe and effective cell infusion.

On April 23, 2026, he received the personalized CAR-T cell infusion. During his hospitalization, Muhammad experienced only mild and manageable cytokine release syndrome, with no serious neurotoxicity reported. Observably, his clinical condition improved rapidly; his severe cancer-related pain subsided considerably, and his reliance on opioid medications dropped dramatically. Pre-discharge tests revealed reduced lesions and a normalization of significant laboratory indicators, marking a positive turnaround in his health.

Throughout this challenging journey, Jiahui’s international medical team provided comprehensive support, including translation services and halal meals to cater to his cultural and religious needs. Reflecting on his experience, Muhammad expressed gratitude, stating, “The Chinese people have been very accommodating. Doctors, nurses, and all staff were incredibly helpful.”

Following his successful treatment, he was discharged on May 7, 2026, and is expected to continue with regular follow-up checks and imaging in Pakistan.

A Testament to Medical Advance

This case highlights not only the capabilities of Jiahui International Cancer Center in CAR-T treatments for refractory lymphomas but also its dedication to offering standardized, patient-focused medical services across borders for individuals battling complex oncological conditions. The advancements in CAR-T therapy are paving the way for transformative outcomes in the lives of patients like Muhammad, showcasing a promising future for innovative cancer treatments worldwide.